<DOC>
	<DOCNO>NCT00542152</DOCNO>
	<brief_summary>PHASE : IV TYPE OF STUDY : With direct benefit . DESCRIPTIVE : Multicenter , randomize , open label study . INCLUSION CRITERIA : Steroid-refractory ulcerative colitis . OBJECTIVES : To compare efficacy cyclosporine infliximab steroid- refractory attack ulcerative colitis . STUDY TREATMENTS : Cyclosporine 2mg/kg/day intravenous ( IV ) 7days Neoral 4mg/kg/day orally 3 month . Infliximab 5mg/kg Weeks 0 , 2 6 . NUMBER OF PATIENTS : 50 patient group i.e . total 100 patient . INCLUSION PERIOD : 24 month . STUDY DURATION : 27 month . MAIN EVALUATION CRITERIA : Clinical response D7 accord Lichtiger Index score AND Clinical Remission D98 accord Mayo Disease Activity Index score SECONDARY EVALUATION CRITERIA : Clinical remission D98 ( accord Mayo Disease Activity Index score ) Endoscopic response Colectomy rate Tolerance</brief_summary>
	<brief_title>Study Comparing Cyclosporine With Infliximab Steroid-refractory Severe Attacks Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Age &gt; 18 year . Diagnosis UC accord LennardJones criterion ( Appendix 1 ) . Endoscopically demonstrated colorectal lesion localize anal margin extend least 15cm proximally . Severe acute flare UC Lichtiger Index score &gt; 10 . Refractoriness high dose intravenous steroid therapy ( ≥ 0.8 mg/kg/d methylprednisolone equivalent ) give least 5 day . Adequate contraception male female subject childbearing potential , continue throughout study least 3 month study termination . Pregnant breastfeed woman . Previous treatment cyclosporine infliximab . Azathioprine 6mercaptopurine treatment initiate 4 week inclusion . Indication immediate surgery . History colorectal dysplasia . Diagnosis Crohn 's disease . Positive stool test amoebiasis and/or positive bacteriological culture Salmonella , Shigella , Yersinia Campylobacter and/or presence Clostridium difficile B toxin stool . Renal failure ( creatininemia &gt; upper limit normal laboratory value ) . Uncontrolled high blood pressure . HIV , HBV viral infection ( except presence positive antiHBs antibody ) serology old 3 month . Uncontrolled bacterial active viral infection . Past medical history malignant condition last 5 year ( include leukaemia , lymphoma myelodysplasia ) except basocellular cutaneous cancer . Past medical history myocardial infarction heart failure . Intradermal reaction Tuberculin ( Tubertest® 5 unit ) &gt; 5mm . Active tuberculosis Untreated latent tuberculosis ( see national recommendation . Appendix 2 ) . Abnormal blood count polynuclear neutrophil &lt; 1,500 G/L white cell &lt; 3,000 , platelet &lt; 100,000 G/L . Unexplained rise higher 3 time normal level transaminase , alkaline phosphatase and/or high twice normal level bilirubin . Noncompliant subject . Participation another therapeutic study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>IBD</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>refractory steroid</keyword>
</DOC>